Scientific Account Manager - Stem Cell Solutions

Revvity (NYSE: RVTY) will present at two investor conferences, chief executive officer Prahlad Singh said in an announcement on October 13, 2026. Singh will speak at the Jefferies Global Healthcare Conference on November 17, 2026, at 8:00 GMT. He will then appear at the Evercore Healthcare Conference on December 2, 2026, at 9:10 ET. Both sessions are fireside chats on the company's progress and strategic priorities. Live audio webcasts will be available on the Revvity website. Replays will be posted on its Investor Relations site for at least 30 days. The Waltham, Massachusetts, company had 2025 revenue of $2.9 billion and about 11,000 employees.

Revvity has launched the GSP T1D 3plex kit, a CE-IVDR-certified solution for early detection of type 1 diabetes in children. The fully automated multiplex autoantibody detection system uses capillary dried blood spots for scalable sample collection and can identify at-risk individuals months or years before symptoms appear. The kit processes samples on Revvity's GSP instrument, a high-throughput platform used in newborn screening. It detects children at risk of developing type 1 diabetes before significant beta-cell damage occurs, potentially preventing life-threatening diabetic ketoacidosis episodes. The solution is designed for emerging national T1D screening programmes and will initially be available in Europe and markets accepting CE IVD-marked products. It is not FDA-cleared for use in the United States. Revvity, which reported 2025 revenue of $2.9 billion, serves customers across pharmaceutical, biotech, diagnostic labs, and academic sectors globally.

Revvity (NYSE:RVTY) shares up 5.2% - time to buy? September 24, 2026 Key points. * Revvity shares rose 5.2% to about $149.49, supported by the launch of an IVDR-certified solution for early Type 1 diabetes detection, which could expand its European diagnostics business. * The company recently beat quarterly earnings and revenue estimates, reporting $1.41 in EPS and $729.7 million in revenue, while maintaining fiscal 2026 EPS guidance of $5.30-$5.40 despite a 1.3% year-over-year revenue decline. * Analysts remain cautious: Revvity has a consensus "Hold" rating and an average price target of $116.57, well below its recent trading level; the stock also carries a high P/E ratio of 71.9 and has seen recent insider selling. * MarketBeat previews top five stocks to own in October. Shares of Revvity Inc. (NYSE:RVTY - Get Free Report) were up 5.2% on Thursday. The company traded as high as $148.53 and last traded at $149.4930. Approximately 1,039,798 shares were traded during mid-day trading, a decline of 29% from the average daily volume of 1,467,490 shares. The stock had previously closed at $142.11. More Revvity news. Here are the key news stories impacting Revvity this week: * New diabetes-testing solution: Revvity launched an IVDR-certified solution designed to help detect Type 1 diabetes at an early stage. The certification may improve the product's commercial prospects in Europe and strengthen Revvity's position in diagnostic testing. * Recent operating momentum: Revvity's latest reported quarter exceeded analyst expectations for both earnings and revenue, while its full-year 2026 EPS guidance remains $5.30-$5.40. The diabetes launch gives investors an additional potential growth catalyst as the company works to offset modest year-over-year revenue pressure. * Analyst stance remains cautious: Goldman Sachs maintained a Hold rating, consistent with the broader consensus Hold view. Several firms have assigned price targets below the stock's recent trading range, suggesting investors may already be pricing in considerable improvement. * Insider selling: Insider Maxwell Krakowiak sold 1,631 shares for approximately $235,728, reducing his direct ownership by nearly 10%. The transaction is relatively small compared with Revvity's market value, but it may add modest selling pressure or investor caution after the stock's strong run. Analysts set new price targets. RVTY has been the subject of several recent analyst reports. Royal Bank Of Canada assumed coverage on shares of Revvity in a research note on Tuesday, September 1st. They issued a "sector perform" rating and a $135.00 target price for the company. Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research report on Sunday, August 16th. KeyCorp increased their price objective on shares of Revvity from $125.00 to $165.00 and gave the company an "overweight" rating in a research note on Friday, September 4th. Zacks Research raised Revvity from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 4th. Finally, Evercore reiterated an "outperform" rating on shares of Revvity in a report on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $116.57. Discover more AI Stocks Analysis Stock Ratings Screener Options Profit Calculator Revvity trading up 6.5%. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. The stock has a market capitalization of $16.88 billion, a PE ratio of 71.90, a PEG ratio of 2.61 and a beta of 1.09. The stock's 50 day simple moving average is $122.53 and its two-hundred day simple moving average is $105.76. Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, topping analysts' consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The company had revenue of $729.69 million for the quarter, compared to analysts' expectations of $702.96 million. During the same quarter in the previous year, the firm posted $1.18 EPS. Revvity's revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts expect that Revvity Inc. will post 5.36 EPS for the current year. Revvity dividend announcement. The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a dividend of $0.07 per share. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity's dividend payout ratio (DPR) is currently 13.33%. Insider activity at Revvity. In other Revvity news, insider Tajinder S. Vohra sold 7,330 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at $934,738.80. This represents a 52.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider directly owned 14,781 shares of the company's stock, valued at $2,136,297.93. The trade was a 9.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 9,046 shares of company stock worth $1,277,685. Insiders own 0.85% of the company's stock. Institutional trading of Revvity. A number of institutional investors have recently added to or reduced their stakes in RVTY. Public Employees Retirement System of Ohio bought a new position in shares of Revvity in the second quarter valued at approximately $3,845,000. Bank of New York Mellon Corp bought a new position in Revvity in the 2nd quarter valued at $78,766,000. Tocqueville Asset Management L.P. purchased a new position in shares of Revvity during the 2nd quarter valued at $4,791,000. California State Teachers Retirement System increased its holdings in shares of Revvity by 19.8% in the first quarter. California State Teachers Retirement System now owns 133,809 shares of the company's stock worth $11,723,000 after purchasing an additional 22,075 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Revvity by 5.8% in the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company's stock worth $41,048,000 after buying an additional 20,278 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock. About Revvity. Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing. The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening. Revvity was established in 2023 following the separation of PerkinElmer's Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Revvity, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list. While Revvity currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps. Continue following MarketBeat